Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nektar Therapeutics

24.59
-1.2500-4.84%
Post-market: 24.20-0.3900-1.59%18:12 EDT
Volume:3.86M
Turnover:96.02M
Market Cap:305.09M
PE:-2.58
High:25.74
Open:24.96
Low:24.19
Close:25.84
Loading ...

Nektar Therapeutics - Increases Authorized Shares to 390 Mln - SEC Filing

THOMSON REUTERS
·
07 Jun

Nektar Therapeutics Amends Bylaws, Increases Authorized Shares and Announces Reverse Stock Split

Reuters
·
07 Jun

Nektar Therapeutics Announces 1-for-15 Reverse Stock Split Effective June 8, 2025

Reuters
·
05 Jun

Nektar Therapeutics Elects New Board, Approves Key Proposals

TIPRANKS
·
28 May

Nektar Therapeutics Conducted Annual Stockholders Meeting

Reuters
·
28 May

Nektar Therapeutics' Chief Legal Officer Mark A. Wilson Reports Disposal of Common Shares

Reuters
·
22 May

Nektar Therapeutics CEO Howard W. Robin Reports Disposal of Common Shares

Reuters
·
22 May

Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)

TIPRANKS
·
19 May

Nektar Therapeutics to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference

Reuters
·
14 May

Piper Sandler Reaffirms Their Buy Rating on Nektar Therapeutics (NKTR)

TIPRANKS
·
09 May

Nektar Therapeutics reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Nektar Therapeutics Q1 EPS $(0.24) Misses $(0.16) Estimate, Sales $10.46M Miss $15.36M Estimate

Benzinga
·
09 May

Nektar Therapeutics Q1 Income From Operations USD -44.535 Million

THOMSON REUTERS
·
09 May

Nektar Therapeutics expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
07 May

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

PR Newswire
·
02 May

Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know

Zacks
·
01 May

Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00

GuruFocus.com
·
12 Apr

Nektar Therapeutics Shares Rise After Upgrade From Jefferies

MT Newswires Live
·
12 Apr

Nektar Therapeutics Raised to Buy From Hold by Jefferies

Dow Jones
·
11 Apr

Jefferies Upgrades Nektar Therapeutics to Buy From Hold, Adjusts Price Target to $2 From $1

MT Newswires Live
·
11 Apr